Primary Sclerosing Cholangitis: Is "Microbiome Sequestration" the Key to Stopping the Gut-Liver Attack?
In 2026, the "Gut-Liver Axis" is no longer just a theory; it is a primary therapeutic target. Scientists have discovered that "leaky gut" in IBD patients allows harmful bacteria and toxins to travel directly to the liver, triggering the immune attack on bile ducts seen in PSC. A novel approach being tested this year involves Carbalive, a "lab-designed" carbon-based device that is swallowed like...
0 Comments 0 Shares 14 Views 0 Reviews